

Injection drug use and Hepatitis C as risk factors for mortality in HIV-infected individuals: the Antiretroviral Therapy Cohort Collaboration

Table S1: Mutually adjusted mortality HR for IDU v. Non-IDU and HCV-infected v. HCV-uninfected accounting for misclassification bias

Sensitivity IDU	Specificity IDU	Sensitivity HCV+	Specificity HCV+	Mutually adjusted mortality HR IDU vs. Non-IDU HCV+ vs. HCV-		Ratio of HRs
				1	1	
0.8	0.95	1	1	2.01	2.03	1.01
1	1	0.8	0.95	1.56	2.52	1.62
0.8	0.95	0.8	0.95	2.01	2.51	1.25

IDU assumed route of HIV transmission via injection drug use; HCV+ Hepatitis C infected; HCV- Hepatitis C uninfected

Table S2: Sensitivity analysis excluding patients with “other/unknown” risk group. Unadjusted and adjusted mortality hazard ratios for IDU (v. Non IDU) and HCV infected (v. HCV uninfected) up to three years after starting ART from Cox models stratified by cohort

	Deaths/patients	Unadjusted			Controlling for age, sex, baseline CD4, RNA and AIDS diagnosis			Additionally controlling for IDU/HCV		
		HR	95% CI	p	HR	95% CI	p	HR	95% CI	p
All patients	985/30254									
IDU	232/3374	2.63	(2.25, 3.06)	<0.001	2.84	(2.43, 3.32)	<0.001	1.61	(1.29, 2.01)	<0.001
HCV+	290/4391	2.64	(2.29, 3.04)	<0.001	2.79	(2.42, 3.22)	<0.001	2.08	(1.69, 2.56)	<0.001

IDU assumed route of HIV transmission via injection drug use; HCV+ Hepatitis C infected

Table S3: Number (%) of deaths and cause-specific mortality rate (MR) per 1000 person years overall and by HCV status

Cause of death	No. deaths (%) and Mortality Rate per 1000 person years					
	overall		HCV-uninfected		HCV-infected	
	N (%)	MR (95% CI)	N (%)	MR (95% CI)	N (%)	MR (95% CI)
All	1116 (100)	14.47 (13.64,15.34)	810 (100)	12.18 (11.37,13.05)	306 (100)	28.78 (25.73,32.19)
AIDS	459 (41.1)	5.95 (5.43,6.52)	378 (46.7)	5.68 (5.14, 6.29)	81 (26.5)	7.62 (6.13,9.47)
Non-AIDS infection	84 (7.5)	1.09 (0.88,1.35)	57 (7.0)	0.86 (0.66, 1.11)	27 (8.8)	2.54 (1.74,3.70)
Liver-related	69 (6.2)	0.89 (0.71,1.13)	18 (2.2)	0.27 (0.17,0.43)	51 (16.7)	4.80 (3.65, 6.31)
Non-AIDS malignancy	103 (9.2)	1.34 (1.10,1.62)	80 (9.9)	1.20 (0.97,1.50)	23 (7.5)	2.16 (1.44,3.26)
MI/IHD	22 (2.0)	0.29 (0.19,0.43)	21 (2.6)	0.32 (0.21,0.48)	1 (0.3)	0.09 (0.01,0.67)
Stroke	10 (0.9)	0.13 (0.07,0.24)	7 (0.9)	0.11 (0.05,0.22)	3 (1.0)	0.28 (0.09,0.87)
Renal failure	12 (1.1)	0.16 (0.09,0.27)	9 (1.1)	0.14 (0.07,0.26)	3 (1.0)	0.28 (0.09,0.87)
Violence*	52 (4.7)	0.67 (0.51,0.88)	28 (3.5)	0.42 (0.29,0.61)	24 (7.8)	2.26 (1.51,3.37)
CNS (other than stroke)	16 (1.4)	0.21 (0.13,0.34)	10 (1.2)	0.15 (0.08,0.28)	6 (2.0)	0.56 (0.25,1.26)
Other heart/vascular disease	34 (3.1)	0.44 (0.31,0.62)	22 (2.7)	0.33 (0.22,0.50)	12 (3.9)	1.13 (0.64,1.99)
Respiratory disease*	16 (1.4)	0.21 (0.13,0.34)	10 (1.2)	0.15 (0.08,0.28)	6 (2.0)	0.56 (0.25,1.26)
Other	48 (4.3)	0.62 (0.47,0.83)	35 (4.3)	0.53 (0.38,0.73)	13 (4.3)	1.22 (0.71,2.11)
Unknown*	191 (17.1)	2.48 (2.15,2.85)	135 (16.7)	2.03 (1.71,2.40)	56 (18.3)	5.27 (4.05,6.84)

*Violence includes suicide, substance abuse; Respiratory includes chronic obstructive pulmonary disease (COPD); unknown includes unclassifiable.

MI Myocardial Infarction; IHD Ischaemic Heart Disease; CNS Central Nervous System.

HCV+ Hepatitis C infected